



**ANNUAL REPORT  
2015**



# LETTER TO SHAREHOLDERS

At the beginning of 2015, InnoMedica received a five-year operating license for the production of medicinal products and the wholesale trade of pharmaceuticals from Swissmedic. Thus InnoMedica possesses in Marly (Fribourg) an operational, certified, and GMP compliant production facility. At the same time, considerable progress was made past year in the development of Talidox: the method for efficient loading of the active ingredient has been optimized, the attachment of glycans by chemical linker has been improved, and furthermore the targeting effects of various glycans in animal models has also been evaluated.

At the end of May 2015, InnoMedica carried out its largest ever funding round by raising CHF 1.33 million. The capital was raised by a public offering of shares. In cooperation with PwC auditors, the audit was changed from limited to an ordinary procedure. Overall, the capital increase added nearly 50 new shareholders.

The new resources have enabled the continuation of the Talidox project and appropriate further infrastructure development. InnoMedica decided to spatially separate the development and analysis areas from the GMP production zone. As a consequence of this separation, a new research laboratory was established at Marly Innovation Center which duplicates the entire machinery for liposome production, thereby increasing the efficiency of development work significantly. In addition, the infrastructure has been extended to include an analysis laboratory. The individual production steps can henceforth be monitored analytically and the functional quality of the manufactured products rigorously tested. InnoMedica uses advanced analysis equipment such as UHPLC (Ultra High Performance Liquid Chromatography) and TRPS (Tunable Resistive Pulse Sensing). The newly signed lease with the Marly Innovation Center now includes additional office space, with renewal options for further expansion in the production area.

The major achievement and highlight of 2015 occurred in the fall, as impressive evidence of the effect of glycan targeting was observed in an animal model. This was a direct consequence of the investments in infrastructure and product development. It could be shown that sugar molecules mounted on the surface of the liposome encapsulating the active agent travel to the tumor cell, where the liposomes discharge their payload. This protects all the other cells in the organism, especially those organs involved in the excretion processes e.g. the liver. Secondly,


fewer side effects are observed in the animal model, simultaneously with enhanced concentrations of medicine in the tumor tissue.

During 2015, InnoMedica continued to work unchanged with a streamlined structure. Salary levels were maintained at a moderate level. In return, and since the project began in 2012, the active employees have had the opportunity to become shareholders. These shares have been provided by substantial shareholders for a Management Buy-In Program, resulting in no dilution effect for the remaining shareholders.

## CAPITAL INCREASE 2016

The staggered approach in raising new capital, coupled with the track record of development and efficiency of the company, has proved worthwhile. With this in mind, InnoMedica will address investors in public with its next capital increase in spring 2016.

InnoMedica plans issuing 64,500 shares at CHF 68.50 until May 31, 2016 to procure CHF 4.4 million. In case of oversubscription, a further 12,331 shares worth CHF 845,000 are offered as Greenshoe option). This will secure funding for the clinical study I/IIa, including third-party costs of approximately CHF 2 million (toxicology, hospitals, laboratories, hospital-affiliated organizations) and the current operating expenses for about two years. Translation, i.e. the transfer of new drugs into the clinic, and its institutional funding is currently often discussed in public. However, InnoMedica considers financing through the capital market as the best solution. Previous experience shows this method facilitates quick progress, preservation of the company's independence, and furthermore reduces occurrence of conflicts of interest. Compared to the competition, InnoMedica achieves satisfactory margins even with moderate drug prices due to the innovative approach of InnoMedica's targeting technology in combination with a generically available drug. The development and tangible progress made, encourages and convinces InnoMedica that within a few years Talidox may set the standards for chemotherapy in Switzerland and abroad.



“ After four financing rounds InnoMedica is supported by more than 150 shareholders.

## RISK ASSESSMENT

Through the successful results of the preclinical studies the chances of success have increased substantially, which implies the risk for investors has been correspondingly reduced. Until the final pharmaceutical production and introduction into clinical practice, the challenge is nevertheless still considerable. InnoMedica is confident in addressing these challenges as a small independent company; furthermore, Talidox is not a new drug, but a known substance with innovation. InnoMedica therefore, according to Swissmedic (confirmed in writing), has a simplified authorization procedure for Talidox.

The most important financial risk is considered to be a liquidity risk or cash flow shortage. Turmoil in financial markets can make it difficult to refinance and obtain external capital. In line with the risk profile, only equity capital is generally used for financing the current project. A strong equity financing position can make an important contribution to the reduction of the risk profile of the company. At the same time, the Board is aware that an unnecessary dilution, through early issuance of a large number of shares, is not in the interest of current shareholders.

## DEVELOPMENT OUTLOOK

The good news from the preclinical results show also positive impact on the collaboration with the Swiss oncologists. Leading oncologists recognize the potential of Talidox and the feasibility of InnoMedica,s project. With the support of Dr. Markus Jörger, InnoMedica has at the end of 2015 a precise plan for the clinical trial Phase I/IIa - with the opportunity to continue this directly into Phase IIb (proof of concept). From the medical side, delays are expected to be unlikely. The proximity of the doctors to the patients and their familiarity with the possibilities and limitations of current therapies are of great value.

InnoMedica,s most important task remains to get the drug in the required standard for use in clinical studies into the hospitals as soon as possible. The aim is to carefully balance desire for rapid progress, continued evaluation of the best solution, and further testing and developments of variants. Although InnoMedica is specifically working towards a marketable medicinal product for use in oncology, and wants to start with the clinical trials in the hospital in 2016, it is important to uphold the high quality standards, to finally give patients access to a real solution which exceeds the capabilities of what is currently available.

The Board of InnoMedica Holding AG:



**Dr. Herbert Fröh**  
Chairman  
of the Board



**Dr. Peter Halbherr**  
Delegate  
of the Board

# FINANCIAL STATEMENT

Compared to the previous year 2014, the presentation of the balance sheet and the income statement are adjusted to the new Swiss Code of Obligations (OR) accounting law. The balance sheet and income statement accounts are in accordance with the requirements specified in the OR minimum classification (Art. 959). For comparison, the annual accounts for 2014 are presented according to the new minimum classification.

The income statement is prepared using the total cost method. It is also new that the expenses are recorded in the 2015 financial year without VAT. To allow comparison with last year's performance indicators, the VAT deductions in 2014 are reported separately under **Other operating expenses**. The outsourcing spending at IPAG Inter Personal AG is now booked separately in the appropriate expense accounts (wages, social security, infrastructure and administrative expenses).


A capital increase by InnoMedica Holding AG generated CHF 1.33 million of new capital in 2015. In total 23,169 new shares at a price of CHF 57.50 per share were issued. Part of the raised funds were used during the last year to finance the development of Talidox as planned.

## BALANCE SHEET

Liquidity consists of cash of various currencies (**Cash and cash equivalents**), **Other current receivables**, and **Securities**. On the balance sheet, the liquidity of InnoMedica Holding AG rose as compared to last year by 21% to CHF 938,644. On the balance sheet, **Treasury shares** are listed again as a deduction in equity due to the revision of the law.

The direct 100% participation of the Japanese company, Yamazaki-DDS Co., Ltd. amounted to CHF 200,000. The additional investment in fixed assets in 2015 reached CHF 69,195 (before depreciation). Further, on the liabilities side, new reserves from capital contributions for a tax-free return of capital to shareholders was made. The convertible bonds created in the interim financing in the form of a put option (**Current liabilities**) was exercised by InnoMedica Holding AG and transferred to shares at a price of CHF 46.00 per share.

## BALANCE SHEET ITEMS



## BALANCE SHEET

YEAR	2014	2015
<b>ASSETS</b>	CHF	CHF
Cash and cash equivalents	621,854	808,525
Securities	111,577	101,064
Receivables	-	-
Other current receivables	43,794	29,055
Deferred charges	6,871	-
<b>Total current assets</b>	<b>784,096</b>	<b>938,644</b>
Investments	-	-
Subsidiaries (YDDS)	200,000	200,000
Property, plant and equipment	215,825	228,016
<b>Total non-current assets</b>	<b>415,825</b>	<b>428,016</b>
<b>TOTAL ASSETS</b>	<b>1,199,921</b>	<b>1,366,660</b>
<b>LIABILITIES</b>		
Payables	-	-
Short-term interest-bearing liabilities	598,980	-
Accruals	8,147	19,508
<b>Total short-term liabilities</b>	<b>607,127</b>	<b>19,508</b>
<b>Long-term liabilities</b>	<b>-</b>	<b>-</b>
Share capital	1,100,000	1,123,169
Total legal reserves	2,061,296	4,039,051
Reserves from capital contribution	1,173,384	2,468,219
Other legal reserves	887,912	1,570,832
Loss brought forward	-1,461,700	-2,523,752
Loss of the year	-1,062,051	-1,285,339
Treasury shares	-44,750	-5,978
<b>Total shareholders, equity</b>	<b>592,794</b>	<b>1,347,152</b>
<b>TOTAL LIABILITIES</b>	<b>1,199,921</b>	<b>1,366,660</b>

## INCOME STATEMENT

Expenses have increased only slightly over the previous year. Accordingly, this results in a 21% higher operating loss in 2015 of CHF 1,285,339.

The **development expenses** include all direct development expenditure in the form of pharmaceutical products, the cost of the lab, analytics, and GMP services and research efforts, for the preclinical and clinical studies.

For statistical reporting on fiscal year end, InnoMedica discloses a total of nine employees equivalent to 790 percent full-time posts, which were hired through IPAG Inter Personal AG. At the beginning of the financial year, the employment was at 700 percent. Accordingly, personnel expenses increased by 9% to CHF 625,332.


The infrastructure cost increased by 18% to CHF 128,127 due to an expansion including the addition of a research and development laboratory, a testing laboratory, and extra office space.

Administrative expenses were reduced compared to last year. This in addition to general office expenses also includes the variable staff costs at IPAG, auditing costs, accounting costs of Yamazaki-DDS Co., Ltd., and costs for the general meeting and capital increase.

**General operating expenditure** include fees, insurance, and vehicle expenses. The VAT in 2014 was still recorded with the expenditure. Thus, to make performance indicators comparable, the VAT refunds for 2014 are shown separately.

At the time of reporting, InnoMedica holds **Securities** with a total market value of CHF 101,064. The loss in the income statement of **Allowance securities** resulted from an investment environment with declining gold prices.

### SELECTED ITEMS OF INCOME STATEMENT



## INCOME STATEMENT

YEAR	2014 CHF	2015 CHF
<b>OPERATING INCOME</b>		
Total operating income	-	-
<b>GOODS AND SERVICES EXPENSES</b>		
Development expenses	-209,720	-248,537
<b>Total goods and services expenses</b>	<b>-209,720</b>	<b>-248,537</b>
<b>PERSONNEL EXPENSES</b>		
<b>Total personnel expenses</b>	<b>-572,846</b>	<b>-625,332</b>
<b>OTHER OPERATING EXPENSES</b>		
Infrastructure expenditure	-108,468	-128,127
Administration expenditure	-155,013	-146,421
General operating expenditure	-50,313	-48,903
Correction VAT (2014 incl. & 2015 excl.) <sup>1</sup>	85,881	
<b>Total other operating expenses</b>	<b>-227,913</b>	<b>-323,451</b>
<b>EBITDA</b>	<b>-1,010,479</b>	<b>-1,197,321</b>
Depreciation	-54,173	-57,004
Allowance securities	4,980	-10,796
Translation differences	3,486	-2,749
<b>EBIT</b>	<b>-1,056,186</b>	<b>-1,267,870</b>
Financial expense	-2,277	-9,337
Interest expense convertible bond	-2,980	-7,474
Financial income	500	612
<b>EBT</b>	<b>-1,060,943</b>	<b>-1,284,068</b>
Capital taxes	-1,108	-1,271
<b>LOSS FOR THE YEAR</b>	<b>-1,062,051</b>	<b>-1,285,339</b>

<sup>1</sup> In the financial year 2014 expenses were recorded including VAT. New from the financial year of 2015, only the direct costs are recognized. For comparability of data, the position of Correction VAT is inserted in the previous year.

## CASH FLOW STATEMENT

YEAR	2014 CHF	2015 CHF
Net income	-1,062,051	-1,285,339
+ Δ Interest expense convertible bond	2,980	7,474
+ Δ Depreciation	54,173	57,004
- Δ Securities	25,221	10,513
- Δ (other short-term) receivables	-12,868	14,739
- Δ Deferred charges	-6,871	6,871
+ Δ Payables	-2,646	-
+ Δ Accruals	2,767	11,361
<b>OPERATIVE CASH FLOW</b>	<b>-999,296</b>	<b>-1,177,378</b>
- Δ property, plant, and equipment	-268,178	-69,194
<b>FREE CASH FLOW</b>	<b>-1,267,474</b>	<b>-1,246,572</b>
+ Δ Convertible bond	596,000	-596,000
+ Δ interest expense convertible bond	-	-10,454
<b>RESIDUAL CASH FLOW</b>	<b>-671,474</b>	<b>-1,853,026</b>
+ Δ Common equity	45,900	23,169
+ Δ Capital reserves	657,650	1,977,755
+ Δ Treasury shares	-	38,773
<b>CHANGE IN CASH</b>	<b>32,076</b>	<b>186,671</b>

## STATEMENT OF SHAREHOLDERS, EQUITY

YEAR	2014 CHF	2015 CHF
<b>BALANCE, JANUARY 1<sup>ST</sup></b>	<b>1,047,046</b>	<b>592,794</b>
Common stock issued	45,900	23,169
Change in capital reserves	606,650	1,977,755
Change in treasury shares	-44,750	38,773
<b>BALANCE, DECEMBER 31<sup>ST</sup> (WITHOUT NET INCOME)</b>	<b>1,654,845</b>	<b>2,636,502</b>
Net income	-1,062,051	-1,285,339
<b>BALANCE, DECEMBER 31<sup>ST</sup></b>	<b>592,794</b>	<b>1,347,152</b>



# NOTES FOR FINANCIAL YEAR 2015

## ACCOUNTING

These financial statements have been prepared by applying the new accounting legislation which came as part of the revision of the Code of Obligations in force on 1 January 2013, in accordance with provisions of the Swiss Code of Obligations regarding commercial bookkeeping and accounting.

## VALUATION PRINCIPLES

### FOREIGN CURRENCY

Position of foreign currencies on 31.12.2015 converted at the exchange rates in CHF: 1.087386 CHF/EUR and 1.001 CHF/USD.

### MARKETABLE SECURITIES

Marketable securities are valued at market prices on the day of the accounting. Impairment and translation differences are accounted for in the income statement.

### INVESTMENTS AND FIXED ASSETS

Items such as the subsidiary (100 percent) of Yamazaki-DDS Co., Ltd. and the fixed assets of the laboratory in Marly are reported deducting the necessary depreciation at cost. In consideration of market information or business development, InnoMedica sets up appropriate allowances.

### DEPRECIATION PRACTICE

Tangible assets are depreciated using a declining balance method with at a maximum rate of 20 percent. All depreciated assets, the mobile and immobile machinery and equipment for laboratory, production, and analysis. are at the site in Marly.

### TREASURY SHARES

On the date of Accounting 1,120,778 from 1,123,169 of shares were outstanding and 2,391 of these by InnoMedica Holding AG. At the beginning of the reporting period, InnoMedica Holding AG still held 17,900 as treasury shares. At the reporting date, the current 2,391 treasury shares were valued at the actually paid purchase price of CHF 2.50.

## CLASSIFICATIONS AND NOTES

### SUBSIDIARIES (YDDS)

The purpose of Yamazaki-DDS Co., Ltd. is to maintain patents in the field of liposomal drug delivery system. The share capital of Yamazaki-DDS Co., Ltd. is 10,000,000 yen. The Yamazaki-DDS Co., Ltd. headquartered in Ibaraki, Japan is 100 percent directly owned by the InnoMedica Holding AG.

### RESERVES FROM CAPITAL CONTRIBUTIONS

The reserves from capital contributions in 2014 were recognized by the Federal Tax Administration (FTA) at this level. The reserves from capital contributions in 2015 can only be declared once yearly financial statements have been prepared and therefore their provisional nature should be recognized.

### TREASURY SHARES

In total 15,409 treasury shares were sold at an average purchase price of CHF 45.85 in the financial year, 2015. No repurchases were made.

### FINANCIAL EXPENSES

Financial expense includes bank interest and charges. Interest on the convertible bond are presented separately.

### FINANCIAL INCOME

Financial income includes dividends and interest on bank balances.



“

In the first half 2016, a capital increase of 64,500 shares (plus Greenshoe of 12,331 shares) is planned.

## ADDITIONAL INFORMATION

### FULL-TIME JOBS ANNUAL AVERAGE

On average during the financial year of 2015 less than 10 full-time people were employed. At the reporting date nine people are permanently employed with a work percentage of 790 at IPAG.

### TALIDOX PROJECT COSTS

Since 2012 documentation of previous investments in the Talidox project have been accumulated to allow calculation of the cumulative project expenditure. In this calculation, all costs linked to the project expenses are counted. This includes costs for staff and used infrastructure, depreciation of equipment used, but not expenses for administration, finance, controlling and various operating expenses. Activation of the project expenses in the balance sheet may be considered when the drug Talidox has been proven efficient in the patient and is registered as a medication covered by health insurance. The cumulative project costs amounted at the end of 2015 to CHF 2,636,024.

### TRUST SHARES

Besides its own shares, InnoMedica Holding AG has of 31.12.2015 a total of 61,792 trust shares belonging to shareholders.

### REMUNERATION OF BOARD MEMBERS

The project to develop the cancer drug Talidox requires prudent accounting, which is why the payment of fees is kept to a minimum. As part of their duties as Directors of the company, the Directors have waived compensation and do not receive any fees. Dr. Peter Halbherr receives as General Manager within the IPAG outsourcing a salary in the amount of CHF 88,021.

### SIGNIFICANT SHAREHOLDERS

On the reporting date, Dr. Peter Halbherr had 329,382 (29% of 1,123,169), Dr. Herbert Früh 126,340 (11%) and Dr. Noboru Yamazaki 62,920 shares (6%). No other shareholder had on 31.12.2015 more than 5% of the shares.

### BUSINESS TRANSACTIONS WITH RELATED PARTIES

Transactions with related persons and companies are handled with commercial contract formulas and are completed based on standard market terms.

### INSURANCE VALUE OF TANGIBLE ASSETS

Tangible assets at the production site in Marly are insured for full value up to CHF 280,000 against, and among other things, fire, water, elementary damage and burglary. In addition, there is an additional insurance in case of loss of earnings and additional costs insurance of up to CHF 800,000 against fire and natural forces.

### CARRY FORWARD OF THE NET LOSS

The loss of CHF 1,285,339 is added to the loss carried forward of CHF 2,523,752 and the balance transferred to the new account.

### GOING CONCERN

Half of the share capital and statutory reserves is by December 31, 2015 pursuant to Art. 725 para. 1 CO no longer covered. The current capital requirement corresponds to the business plan and the continuation of the company is ensured by the following measures of the Board: In the first half 2016, a capital increase of 64,500 shares (plus Greenshoe of 12,331 shares) with an issue price of CHF 68.50 per share is planned.



Report of the statutory auditor  
to the General Meeting of  
InnoMedica Holding AG  
Zug

### **Report of the statutory auditor on the financial statements**

As statutory auditor, we have audited the accompanying financial statements of InnoMedica Holding AG, which comprise the balance sheet, income statement, cash flow statement and notes, for the year ended 31 December 2015.

#### *Board of Directors' responsibility*

The Board of Directors is responsible for the preparation of the financial statements in accordance with the requirements of Swiss law and the company's articles of incorporation. This responsibility includes designing, implementing and maintaining an internal control system relevant to the preparation of financial statements that are free from material misstatement, whether due to fraud or error. The Board of Directors is further responsible for selecting and applying appropriate accounting policies and making accounting estimates that are reasonable in the circumstances.

#### *Auditor's responsibility*

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Swiss law and Swiss Auditing Standards. Those standards require that we plan and perform the audit to obtain reasonable assurance whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers the internal control system relevant to the entity's preparation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control system. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of accounting estimates made, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### *Opinion*

In our opinion, the financial statements for the year ended 31 December 2015 comply with Swiss law and the company's articles of incorporation.

### **Report on other legal requirements**

We confirm that we meet the legal requirements on licensing according to the Auditor Oversight Act (AOA) and independence (article 728 CO) and that there are no circumstances incompatible with our independence.



In accordance with article 728a paragraph 1 item 3 CO and Swiss Auditing Standard 890, we confirm that an internal control system exists which has been designed for the preparation of financial statements according to the instructions of the Board of Directors.

We recommend that the financial statements submitted to you be approved.

Further, we draw attention to the fact that half of the share capital and the legal reserves is no longer covered (article 725 para. 1 CO).

PricewaterhouseCoopers AG

A blue ink signature of Simon Bandi, consisting of stylized, overlapping letters.

Simon Bandi  
Audit Expert  
Auditor in Charge

A blue ink signature of Andreas Scheibli, written in a cursive style.

Andreas Scheibli  
Audit Expert

Zürich, 07. March 2016

# GENERAL INFORMATION

<b>BUSINESS IDEA</b>	InnoMedica Holding AG has developed a new generation of cancer treatment, based on an innovative transport system for drugs. Cancer can be treated much more effectively, while reducing the side effects for the patient. In January 2013, InnoMedica Holding AG initiated the project Targeted Liposomal Doxorubicin (Taldiox) with a strategy to develop novel therapeutics for the treatment of tumor diseases and commercialize it. This is a new generation of chemotherapeutic drugs based on well-known cytostatic agent, formulated in a new pharmaceutical form for use in cancer therapy.
<b>THE CORPORATION</b>	InnoMedica Holding AG is an incorporated limited company based in Zug. The company aims to hold, purchase, sell, and manage investments in (listed and unlisted) companies from the sectors of biotechnology and medicine and related sectors or industries that are in any way related to these. Change of purpose since 2012 AGM (additional): The company seeks in particular to establish and develop investments in the fields of biotechnology and medicine. Furthermore, the company offers management services and consultancy for companies in the sectors of biotechnology and medicine.
<b>INVESTMENT OF CASH</b>	InnoMedica Holding AG has evolved from a finance company to an operating company and invested in production and development of its own pharmaceutical products. An active management of liquidity is no longer seen as a priority and replaced by a passive investment strategy.
<b>BOARD</b>	Dr. Herbert Früh (Chairman) Dr. Peter Halbherr (Delegate) Dr. Noboru Yamazaki
<b>LEGAL STRUCTURE</b>	Incorporated limited Company
<b>ESTABLISHED</b>	July 05, 2000
<b>SHARES OUTSTANDING</b>	1,123,169 stocks at face value of CHF 1
<b>CAPITAL INCREASE</b>	Planned; from May 31, 2016 (64,500 shares, plus Greenshoe of 12,331 shares)
<b>LISTING / TRADE</b>	OTC by the Head of Finance, Dr. Jonas Zeller
<b>SECURITY NUMBER</b>	001108236
<b>ISIN-NUMBER</b>	CH0011082366
<b>INVESTOR RELATIONS</b>	Andrea Zurkirchen (Tel. +41 (0)44 383 88 22)
<b>HEADQUARTER</b>	InnoMedica Holding AG, Baarerstrasse 34, CH-6300 Zug
<b>INTERNET</b>	<a href="http://www.innomedica.com">www.innomedica.com</a>
<b>E-MAIL</b>	<a href="mailto:info@innomedica.com">info@innomedica.com</a>

This information is not an offer to purchase or subscribe for shares of InnoMedica Holding AG and may not be distributed in any jurisdiction where it violates any applicable law or regulations, including, without limitation, the United States of America. The information we consider reliable, but InnoMedica Holding AG does not guarantee its completeness or accuracy. Changes of opinions and assessments may be made without notice. Past performance is not indicative of future performance.



## **INNOMEDICA HOLDING AG**

Zug - Switzerland

### **BRANCH OFFICE BERN**

Gesellschaftsstrasse 16, CH-3012 Bern

### **CONTACT**

Phone: +41 (0)44 383 88 22

e-Mail: [info@innomedica.com](mailto:info@innomedica.com)

[WWW.INNOMEDICA.COM](http://WWW.INNOMEDICA.COM)